These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 28257141)

  • 1. Bayesian population finding with biomarkers in a randomized clinical trial.
    Morita S; Müller P
    Biometrics; 2017 Dec; 73(4):1355-1365. PubMed ID: 28257141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A semiparametric Bayesian approach to population finding with time-to-event and toxicity data in a randomized clinical trial.
    Morita S; Müller P; Abe H
    Biometrics; 2021 Jun; 77(2):634-648. PubMed ID: 32339262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarker-based Bayesian randomized phase II clinical trial design to identify a sensitive patient subpopulation.
    Morita S; Yamamoto H; Sugitani Y
    Stat Med; 2014 Oct; 33(23):4008-16. PubMed ID: 24820639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subgroup finding via Bayesian additive regression trees.
    Sivaganesan S; Müller P; Huang B
    Stat Med; 2017 Jul; 36(15):2391-2403. PubMed ID: 28276142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bayesian additive decision trees of biomarker by treatment interactions for predictive biomarker detection and subgroup identification.
    Zhao Y; Zheng W; Zhuo DY; Lu Y; Ma X; Liu H; Zeng Z; Laird G
    J Biopharm Stat; 2018; 28(3):534-549. PubMed ID: 29020511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarker-based Bayesian randomized clinical trial design for identifying a target population.
    Sugitani Y; Morita S; Nakakura A; Yamamoto H
    Stat Med; 2023 Jul; 42(16):2797-2810. PubMed ID: 37078122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bayesian Additive Regression Trees (BART) with covariate adjusted borrowing in subgroup analyses.
    Pan J; Bunn V; Hupf B; Lin J
    J Biopharm Stat; 2022 Jul; 32(4):613-626. PubMed ID: 35737650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bayesian adaptive patient enrollment restriction to identify a sensitive subpopulation using a continuous biomarker in a randomized phase 2 trial.
    Ohwada S; Morita S
    Pharm Stat; 2016 Sep; 15(5):420-9. PubMed ID: 27485377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial design for drug combinations with Bayesian model averaging.
    Jin IH; Huo L; Yin G; Yuan Y
    Pharm Stat; 2015; 14(2):108-19. PubMed ID: 25641851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Bayesian meta-analytic approach for safety signal detection in randomized clinical trials.
    Odani M; Fukimbara S; Sato T
    Clin Trials; 2017 Apr; 14(2):192-200. PubMed ID: 28059578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bayesian inference for randomized clinical trials with treatment failures.
    Shaffer ML; Chinchilli VM
    Stat Med; 2004 Apr; 23(8):1215-28. PubMed ID: 15083479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decision making and uncertainty quantification for individualized treatments using Bayesian Additive Regression Trees.
    Logan BR; Sparapani R; McCulloch RE; Laud PW
    Stat Methods Med Res; 2019 Apr; 28(4):1079-1093. PubMed ID: 29254443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Bayesian prediction model between a biomarker and the clinical endpoint for dichotomous variables.
    Jiang Z; Song Y; Shou Q; Xia J; Wang W
    Trials; 2014 Dec; 15():500. PubMed ID: 25528466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Bayesian sequential design with adaptive randomization for 2-sided hypothesis test.
    Yu Q; Zhu L; Zhu H
    Pharm Stat; 2017 Nov; 16(6):451-465. PubMed ID: 28980435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of single-arm vs. randomized phase II clinical trials: a Bayesian approach.
    Sambucini V
    J Biopharm Stat; 2015; 25(3):474-89. PubMed ID: 24896838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bayesian modeling and inference for diagnostic accuracy and probability of disease based on multiple diagnostic biomarkers with and without a perfect reference standard.
    Jafarzadeh SR; Johnson WO; Gardner IA
    Stat Med; 2016 Mar; 35(6):859-76. PubMed ID: 26415924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ASIED: a Bayesian adaptive subgroup-identification enrichment design.
    Xu Y; Constantine F; Yuan Y; Pritchett YL
    J Biopharm Stat; 2020 Jul; 30(4):623-638. PubMed ID: 31782938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incorporating external data into the analysis of clinical trials via Bayesian additive regression trees.
    Zhou T; Ji Y
    Stat Med; 2021 Dec; 40(28):6421-6442. PubMed ID: 34494288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Bayesian interval dose-finding design addressingOckham's razor: mTPI-2.
    Guo W; Wang SJ; Yang S; Lynn H; Ji Y
    Contemp Clin Trials; 2017 Jul; 58():23-33. PubMed ID: 28458054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A dose-finding approach based on shrunken predictive probability for combinations of two agents in phase I trials.
    Hirakawa A; Hamada C; Matsui S
    Stat Med; 2013 Nov; 32(26):4515-25. PubMed ID: 23650098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.